PIK3CA and breast cancer: Recently, the SOLAR-1 trial revealed that the alpelisib plus fulvestrant treatment had a significantly benefit in median OS (37.2 months) compared to fulvestrant alone (22.8 months) for PIK3CA-mutant/HR+/HER-2- BC patients with lung and/or liver metastasis (138).